1. Eli Lilly lowers insulin costs as coronavirus crisis deepens— IQVIA launches new COVID-19 trial matching service — Inovio begins clinical trial of COVID-19 vaccine — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Fisher Wallace files citizen petition over FDA’s class III designation for CES

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Feb 21, 2020 at 12:12 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Nov 21, 2001
    Likes Received:
    via Fisher Wallace Laboratories of New York has filed a citizen’s petition with the U.S. FDA regarding the agency’s proposed class III designation for cranial electrotherapy stimulators (CES) for treatment of depression. The company argued that the agency disallowed evidence at an advisory hearing regarding this therapy provided by direct rather than alternating current, but also that the FDA had reneged on an earlier decision to classify these devices as class II devices.

    article source